Document:

EX-10.16

 Exhibit 10.16 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE
SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 

1LIFE HEALTHCARE, INC. 

WARRANT TO PURCHASE SERIES G PREFERRED STOCK 
  

					
	No. PW-G[    ]	 		  	[                    ], 2015
			
		 	VOID AFTER [                         ], 2020	  	

 THIS CERTIFIES THAT, for value received,
«WARRANTHOLDER» (the “Holder”), is entitled to subscribe for and purchase from 1LIFE HEALTHCARE, INC., a Delaware corporation (the
“Company”), «Shares» shares of Exercise Shares at the Exercise Price (each subject to adjustment as provided herein). 

1. DEFINITIONS. As used herein, the following terms shall have the following respective meanings: 

(a) “Exercise Period” shall mean the period commencing on the date hereof and ending on the fifth anniversary of
the date hereof, unless sooner terminated as provided below. 
 (b) “Exercise Price” shall mean
$                per Exercise Share, subject to adjustment pursuant to Section 5 below. 

(c) “Exercise Shares” shall mean shares of the Company’s Series G Preferred Stock, par value $0.001
issuable upon exercise of this Warrant, subject to adjustment as set forth in Section 5. 
 2. EXERCISE
OF WARRANT. 
 2.1 The rights represented by this Warrant may be exercised in whole or in part at
any time during the Exercise Period, by delivery of the following to the Company at its address set forth above (or at such other address as it may designate by notice in writing to the Holder): 

(a) An executed Notice of Exercise in the form attached hereto; 

(b) Payment of the Exercise Price either (i) in cash or by check, or (ii) by cancellation of indebtedness; and 

(c) This Warrant. 
 Upon
the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased, registered in the name of the Holder or persons affiliated with the Holder, if the Holder so designates, shall be issued and
delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised. In the 

  
 1. 

 
event that this Warrant is being exercised for less than all of the then-current number of Exercise Shares purchasable hereunder, the Company shall, concurrently with the issuance by the Company
of the number of Exercise Shares for which this Warrant is then being exercised, issue a new Warrant exercisable for the remaining number of Exercise Shares purchasable hereunder. 

The person in whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to
have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or certificates, except that, if the date of such
surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the stock transfer books are
open. 
 2.2 Net Exercise. Notwithstanding any provisions herein to the contrary, if the fair market value of one Exercise
Share is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash, the Holder may elect to receive shares equal to the value (as determined below) of this Warrant (or the
portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with the properly endorsed Notice of Exercise in which event the Company shall issue to the Holder a number of Exercise Shares computed
using the following formula: 
  

			
		  	X = Y (A-B)
		  	            A
		
	Where X =	  	the number of Exercise Shares to be issued to the Holder
		
	Y =	  	the number of Exercise Shares purchasable under the Warrant or, if only a portion of the Warrant is being exercised, that portion of the Warrant being canceled (at the date of such calculation)
		
	A =	  	the fair market value of one Exercise Share (at the date of such calculation)
		
	B =	  	Exercise Price (as adjusted to the date of such calculation)

 For purposes of the above calculation, the fair market value of one Exercise Share shall be determined
by the Company’s Board of Directors in good faith; provided, however, that 
 (a) where a public market exists for the
Company’s common stock at the time of such exercise, the fair market value per Exercise Share shall be the product of (x) the average of the closing bid prices of the common stock or the closing price quoted on the national securities
exchange on which the common stock is listed as published in the Wall Street Journal for the five (5) trading day period ending five (5) trading days prior to the date of determination of fair market value and (y) the number of
shares of common stock into which each Exercise Share is convertible at the time of such exercise, as applicable; and 
 (b) if the
Warrant is exercised in connection with the Company’s initial public offering of common stock, the fair market value per Exercise Share shall be the product of (x) the per share offering price to the public of the Company’s initial
public offering and (y) the number of shares of common stock into which each Exercise Share is convertible at the time of such exercise, as applicable. 

  
 2. 

 3. COVENANTS OF THE COMPANY.

 3.1 Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise Shares that may be issued upon
the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. If at any time during the
Exercise Period the number of authorized but unissued Exercise Shares shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its
authorized but unissued Exercise Shares to such number of shares as shall be sufficient for such purposes. 
 4.
REPRESENTATIONS OF THE HOLDER. 
 4.1 Acquisition of Warrant for
Personal Account. The Holder represents and warrants that it is acquiring the Warrant and the Exercise Shares solely for its account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares or any part
thereof. The Holder also represents that the entire legal and beneficial interests of the Warrant and Exercise Shares the Holder is acquiring is being acquired for, and will be held for, its account only. 

4.2 Securities Are Not Registered. 

(a) The Holder understands that the Warrant and the Exercise Shares have not been registered under the Securities Act of 1933, as
amended (the “Act”) on the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its
representations, the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the
securities. The Holder has no such present intention. 
 (b) The Holder recognizes that the Warrant and the Exercise Shares must be
held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register the Warrant or the Exercise Shares of the Company, or
to comply with any exemption from such registration. 
 (c) The Holder is aware that neither the Warrant nor the Exercise Shares may
be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met, including, among other things, the existence of a public market for the shares, the availability of certain current public information about the Company, the
resale following the required holding period under Rule 144 and the number of shares being sold during any three month period not exceeding specified limitations. The Holder is aware that the conditions for resale set forth in Rule 144 have not been
satisfied and that the Company presently has no plans to satisfy these conditions in the foreseeable future. 

  
 3. 

 4.3 Disposition of Warrant and Exercise Shares. 

(a) The Holder further agrees not to make any disposition of all or any part of the Warrant or Exercise Shares in any event unless and
until: 
 (i) The Company shall have received a letter secured by the Holder from the Securities and Exchange Commission (the
“Commission”) stating that no action will be recommended to the Commission with respect to the proposed disposition; 

(ii) There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in
accordance with said registration statement; or 
 (iii) The Holder shall have notified the Company of the proposed disposition and
shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished the Company with an opinion of counsel, reasonably
satisfactory to the Company, for the Holder to the effect that such disposition will not require registration of such Warrant or Exercise Shares under the Act or any applicable state securities laws. The Company agrees that it will not require an
opinion of counsel with respect to transactions under Rule 144 of the Act, except in unusual circumstances. Furthermore, the Company shall not require the Holder to provide an opinion of counsel if the transfer is to an affiliate of the Holder. 

(b) The Holder understands and agrees that all certificates evidencing the shares to be issued to the Holder may bear the following
legend: 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY
MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 

4.4 Accredited Investor Status. The Holder is an “accredited investor” as defined in Regulation D promulgated under the
Act. 
 5. ADJUSTMENT OF EXERCISE PRICE AND
EXERCISE SHARES. In the event of changes in the series of equity securities of the Company comprising the Exercise Shares by reason of stock dividends, splits, recapitalizations, conversions, reclassifications,
combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the number and class of Exercise Shares available under the Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the
Holder of the Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares
until after the event requiring adjustment; provided, however, that such adjustment shall not be made with respect to, and this Warrant shall terminate if not exercised prior to, the events set forth

  
 4. 

 
in Section 7 below. For purposes of this Section 5, the “Aggregate Exercise Price” shall mean the aggregate Exercise Price payable in connection with the
exercise in full of this Warrant. Upon any adjustment in accordance with this Section 5, the Company shall give notice thereof to the Holder, which notice shall state the event giving rise to the adjustment, the Exercise Price as adjusted and
the number, class, and kind of shares or other property purchasable upon the exercise of the rights under this Warrant, setting forth in reasonable detail the method of calculation of each. The Company shall, upon the written request of any Holder,
furnish or cause to be furnished to such Holder a certificate setting forth (i) such adjustments, (ii) the Exercise Price at the time in effect, (iii) the number, class, and kind of shares and the amount, if any, of other property
that at the time would be received upon exercise of this Warrant, and (iv) such further information and terms with respect to the events and transactions giving rise to such adjustment as the Holder may reasonably request in confirming the
appropriateness of such adjustment. 
 6. FRACTIONAL SHARES. No fractional shares shall be issued
upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) to be issued upon exercise of this Warrant shall be aggregated for purposes of determining whether the exercise would
result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such
fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of one Exercise Share by such fraction. 

7. EARLY TERMINATION. In the event of, at any time during the Exercise Period any Asset Transfer or
Acquisition (each as defined in the Company’s Amended and Restated Certificate of Incorporation as in effect on the date hereof), the Company shall provide to the Holder ten (10) days advance written notice of such Asset Transfer or
Acquisition, and this Warrant shall terminate unless exercised immediately prior to the date of the closing of such Asset Transfer or Acquisition. 

8. NOTIFICATION OF CERTAIN EVENTS. Prior
to the expiration of this Warrant, in the event that the Company shall authorize: 
 (a) the issuance of any dividend or other
distribution on the capital stock of the Company (other than (i) dividends or distributions otherwise provided for in Section 5, (ii) repurchases of common stock issued to or held by employees, officers, directors or consultants of
the Company or its subsidiaries upon termination of their employment or services pursuant to agreements providing for the right of said repurchase; (iii) repurchases of common stock pursuant to rights of first refusal or first offer in favor of
the Company; or (iv) repurchases of capital stock of the Company in connection with the settlement of disputes with any stockholder), whether in cash, property, stock or other securities; or 

(b) the voluntary liquidation, dissolution or winding up of the Company; 

the Company shall send to the Holder of this Warrant at least ten (10) days prior written notice of the date on which a record shall be
taken for any such dividend or distribution specified in clause Error! Reference source not found. or the expected effective date of any such other event specified in clause (b). 

  
 5. 

 9. MARKET
STAND-OFF AGREEMENT. The Holder hereby agrees that such Holder shall not sell, transfer, make any short sale of, grant any option for the
purchase of, or enter into any hedging or similar transaction with the same economic benefit as a sale, any common stock of the Company (“Common Stock”) or other securities of the Company held by such Holder immediately prior
to the effectiveness of the registration statement for such offering (other than those included in the registration or acquired in or following such registration) during the 180-day period following the
effective date of the Company’s first firm commitment underwritten public offering of its Common Stock registered under the Act (the “Initial Offering”) (or such longer period, not to exceed 18 days after the expiration
of the 180-day period, as the underwriter and the Company may request in order to comply with applicable regulations), and that such Holder shall execute the standard
lock-up agreement used in the Initial Offering; provided that all officers and directors of the Company and holders of at least one percent (1%) of the Company’s voting securities are bound by and
have entered into similar agreements. The foregoing provisions of this Section 9 shall apply only to the Initial Offering and shall not apply to (i) the sale of any shares to an underwriter pursuant to an underwriting agreement,
(ii) a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or (iii) a
registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the future. The underwriters in connection with such registration are intended third-party beneficiaries of
this Section 9 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. The Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in
connection with such registration that are consistent with this Section 9 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the
underwriters shall apply pro rata to all holders subject to such agreements, based on the number of shares subject to such agreements, unless otherwise waived by the holders of a majority of the then-outstanding shares subject to such agreements.

 10. NO STOCKHOLDER RIGHTS. This Warrant in and of itself shall not entitle the
Holder to any voting rights or other rights as a stockholder of the Company. 
 11. TRANSFER OF
WARRANT. Subject to applicable laws and the restriction on transfer set forth on the first page of this Warrant, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney, upon
delivery of this Warrant and the form of assignment attached hereto to any transferee designated by the Holder. The transferee shall sign an investment letter in form and substance satisfactory to the Company. 

12. LOST, STOLEN, MUTILATED OR DESTROYED
WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender
thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen,
mutilated or destroyed Warrant shall be at any time enforceable by anyone. 
 13.
AMENDMENT. Any term of this Warrant may be amended or waived only with the written consent of the Company and the Holder. 

  
 6. 

 14. NOTICES, ETC. All notices required or
permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if
not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) three (3) days after deposit with a nationally recognized overnight
courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at the address listed on the signature page and to the Holder at address first listed above or at such other address as the
Company or Holder may designate by ten (10) days advance written notice to the other parties hereto. 
 15.
ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein. 

16. GOVERNING LAW. This Warrant and all rights, obligations and liabilities hereunder shall be
governed by and construed under the laws of the State of Delaware as applied to agreements among Delaware residents, made and to be performed entirely within the State of Delaware without giving effect to conflicts of laws principles. 

  
 7. 

 IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its duly authorized officer as of the date first written above. 
  

			
	1LIFE HEALTHCARE, INC.
		
	By:	 	  

		 	THOMAS H. LEE
		 	Chief Executive Officer

  

			
	Address:	 	P.O. Box 779
		 	San Francisco, CA 94104

 1LIFE HEALTHCARE, INC. 

WARRANT TO PURCHASE SERIES G PREFERRED STOCK –
SIGNATURE PAGE 

 NOTICE OF EXERCISE 

TO: 1LIFE HEALTHCARE, INC. 

(1)     ☐ The undersigned hereby elects to purchase ________ shares of Series G Preferred Stock (the
“Exercise Shares”) of 1LIFE HEALTHCARE, INC. (the “Company”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the
exercise price in full, together with all applicable transfer taxes, if any. 
 ☐ The undersigned hereby elects to purchase ________
shares of Series G Preferred Stock (the “Exercise Shares”) of 1LIFE HEALTHCARE, INC. (the “Company”) pursuant to the terms of the net exercise
provisions set forth in Section 2.2 of the attached Warrant, and shall tender payment of all applicable transfer taxes, if any. 

(2) Please issue a certificate or certificates representing said Exercise Shares in the name of the undersigned or in such other name
as is specified below: 
  
  

(Name) 
  

 
  

 
 (Address) 

(3) The undersigned represents that (i) the aforesaid Exercise Shares are being acquired for the account of the undersigned for
investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares; (ii) the undersigned is aware of the Company’s
business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned is experienced in making
investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own interests; (iv) the
undersigned understands that Exercise Shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the
registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the Securities Act, they
must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the aforesaid Exercise Shares may not be sold pursuant to Rule 144 adopted
under the Securities Act unless certain conditions are met and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the availability of current information to the
public about the Company and the Company has not made such information available and has no present plans to do so; and (vi) the undersigned agrees not to make any disposition of all or any part of the aforesaid shares of Exercise Shares unless
and until there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or, if reasonably requested by the Company, the
undersigned has provided the Company with an opinion of counsel satisfactory to the Company, stating that such registration is not required. 
  

					
	  
 (Date)
	 		  	  
 (Signature)

			
		 		  	  
 (Print name)

 ASSIGNMENT FORM 

(To assign the foregoing Warrant, execute this form 

and supply required information. Do not use this 

form to purchase shares.) 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby
are hereby assigned to 
  

			
	Name:	 	                    
		 	  
 (Please
Print)

	Address:	 	                            
		 	  
 (Please
Print)

  

			
	Dated: __________, 20__	 	

  

			
	Holder’s	 	
	Signature:	 	  

		
	Holder’s	 	
	Address:	 	  

 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant,
without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.EX-10.17

 Exhibit 10.17 

1LIFE HEALTHCARE, INC. 

AGREEMENT 
 for 

AMIR DAN RUBIN 
 This
Agreement (this “Agreement”), is made and entered into as of June 27, 2017 by and between Amir Dan Rubin (“Executive”) and 1Life Healthcare, Inc. (the “Company”).     

1.         Employment by the Company. 

1.1 Position. Executive shall serve as the President and Chief Executive Officer of the Company, reporting to the Board of Directors of
the Company (the “Board”). Executive’s anticipated start date will be August 7, 2017 (the “Start Date”). 

1.2 Duties and Location. Executive shall perform such duties as are customarily associated with the positions of President and Chief
Executive Officer and such other duties consistent with such positions as are assigned to Executive by the Board. Executive’s primary office location shall be the Company’s headquarters located in the San Francisco, California area.
Subject to the terms of this Agreement, the Company reserves the right to reasonably require Executive to perform Executive’s duties at places other than Executive’s primary office location from time to time including reasonable business
travel. 
 1.3 Policies and Procedures. The employment relationship between the parties shall be governed by the general employment
policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement shall control. 

2.         Base Compensation. For services to be rendered hereunder, Executive shall receive a
base salary at the rate of $600,000 per year (the “Base Salary”), less required payroll deductions and withholdings and payable in accordance with the Company’s regular payroll schedule. 

3.         Sign-On Bonus. 

3.1 Executive will receive a signing and retention bonus in the amount of $250,000, less standard payroll deductions and
withholdings, to be paid to Executive within thirty (30) days of the Start Date (the “Signing Bonus”). This Signing Bonus is an advance and is being paid to Executive prior to being earned by Executive. 

3.2 Executive will earn the Signing Bonus on a pro rata basis over the one-year period following
Executive’s Start Date. 
 3.3 If, at any time during Executive’s first year of employment, Executive resigns his employment
without Good Reason, or the Company terminates Executive’s employment for Cause, Executive agrees to repay a pro-rated portion of the Signing Bonus to the Company within thirty (30) days following Executive’s employment termination
date. Such pro-rated portion will be equal to the Signing Bonus multiplied by a fraction, with the numerator equal to the number of calendar days remaining from the date of Executive’s termination to the one-year anniversary of the Start Date, and the denominator equal to 365. To the extent permitted by applicable law, Executive expressly authorizes the Company to deduct from his final paycheck any unearned amount
of the Signing Bonus. 
 3.4 If at any time: (i) Executive resigns his employment for Good Reason; or (ii) Executive’s
employment is terminated by the Company without Cause; then Executive shall not be required to repay the Signing Bonus or any portion thereof. 

  
 1. 

 4.         Standard Company Benefits.
Executive shall, in accordance with Company policy and the terms and conditions of the applicable Company benefit plan documents, be eligible to participate in the benefit and fringe benefit programs provided by the Company to its executive
officers and other employees from time to time. Any such benefits shall be subject to the terms and conditions of the governing benefit plans and policies and may be changed by the Company in its discretion.  

5.         Expenses. The Company will reimburse Executive for reasonable travel, entertainment
or other expenses incurred by Executive in furtherance or in connection with the performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policy as in effect from time to time. In addition, the
Company agrees to reimburse the Executive for reasonable and documented legal fees incurred in the review, negotiation, drafting and execution of this Agreement, up to a cap of $10,000.  

6.         Equity. Subject to approval by the Board, Executive will be provided with three
(3) separate stock option awards to purchase shares of the Company’s common stock (collectively, the “Options”), pursuant to the Company’s 2017 Equity Incentive Plan (the “Equity Plan”). The Options
will have a per share exercise price equal to the fair market value of the Company’s common stock as of the date of grant as determined by the Board (except as otherwise stated in this agreement with respect to the Short-Term Option), and will
be governed in full by the terms and conditions of the Equity Plan and its associated stock option agreements. The Company will submit the request for approval of the grant of the Options to the Board no later than the next scheduled Board meeting
following the Start Date, which is currently scheduled for September 14, 2017, and will grant the Options as soon as administratively practicable after receiving the Board’s approval.  

6.1 Time-Based Option. The first Option (the “Time-Based Option”) will consist of 7,948,990 shares (the
“Time-Based Initial Number”) (which approximates 7.5% of the fully-diluted capitalization of the Company). Except as provided herein, and subject to Executive’s continuous service with the Company through each such vesting
date, the Time-Based Option will be subject to a five-year vesting schedule, with 20% of the shares subject to such Option to vest on the twelve (12) month anniversary of Executive’s Start Date, and the remaining shares subject to such
Option to vest in equal monthly installments over a forty-eight (48) month period thereafter. Notwithstanding the foregoing, if, as of the date grant of the Time-Based Option, the fair market value of the stock underlying the Time-Based Option
is greater than $4.01 per share, then the number of shares subject to the Time-Based Option shall be increased as of such date (such increase, the “Time-Based Additional Number”) as follows: first, the Company will multiply the
Time-Based Initial Number by the excess of the per share fair market value over $4.01; second, the Company will divide such product by $4.01; and third, the Company will round up such quotient to the nearest whole share. 

6.2 Performance Option. The second Option (the “Performance Option”) will consist of 1,589,798 shares (the
“Performance Initial Number”) (which approximates 1.5% of the fully-diluted capitalization of the Company). Except as provided herein, and subject to Executive’s continuous service with the Company through such vesting date,
the Performance Option will vest upon the earlier of (i) the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the common stock, pursuant to which the common stock is priced
for the initial public offering; and (ii) the Company’s Change in Control (as such term is defined in the Company’s Equity Plan). Notwithstanding the foregoing, if, as of the date of grant of the Performance Option, the fair market
value of the stock underlying the Performance Option is greater than $4.01 per share, then the number of shares subject to the Performance Option shall be increased as of such date (such increase, the “Performance Additional
Number”) as follows: first, the Company will multiply the Performance Initial Number by the excess of the per share fair market value over $4.01; second, the Company will divide such product by $4.01; and third, the Company will round up
such quotient to the nearest whole share. 

  
 2. 

 6.3 Short-Term Option. The third Option (the “Short-Term Option”)
will consist of an option to purchase 249,377 Company common shares (which represents approximately $1,000,000 worth of Company common shares at a fair market value of $4.01). The Short-Term Option will have an exercise price equal to the lower of
$4.01 per share or the fair market value on the date of grant. The Short-Term Option will be fully vested on the date of grant, but will expire on December 15, 2017 if not exercised and purchased prior to such date.     

(i) Gross-Up on Discount. If the exercise price of the Short-Term Option is below the fair
market value on the date of grant (such difference, the “Discount”), and the exercise of the Short-Term Option results in taxable ordinary income to Executive as a result of such Discount, then the Company shall pay, and Executive
shall be entitled to receive, an additional payment (a “Gross-Up Payment”) in an amount such that after the payment of all taxes (including, without limitation, any income or employment taxes,
any interest or penalties imposed with respect to such taxes, and any additional excise tax) on the Discount and on the Gross-Up Payment, Executive shall retain an amount equal to the full Discount. For
purposes of determining the amount of the Gross-Up Payment, Executive shall be deemed to have: paid federal income taxes at the highest marginal rate of federal income and employment taxation for the calendar
year in which the Gross-Up Payment is to be made, and paid applicable state and local income taxes at the highest rate of taxation for the calendar year in which the
Gross-Up Payment is to be made, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. 

7.         Proprietary Information Obligations. 

7.1 Employee Confidential Information and Inventions Assignment Agreement. As a condition of employment, and in consideration for the
benefits provided for in this Agreement (including but not limited to the Options), Executive shall sign and comply with the Employee Confidential Information and Inventions Assignment Agreement (the “Proprietary Information
Agreement”). In addition, Executive agrees to abide by the Company’s policies and procedures, as may be modified from time to time within the Company’s discretion. 

7.2 Third-Party Agreements and Information. Executive represents and warrants that: (a) Executive’s employment by the Company
does not conflict with any prior employment or consulting agreement or other agreement with any third party, (b) Executive will perform Executive’s duties to the Company without violating any such agreement, and (c) Executive has
disclosed to the Company in writing any agreement Executive may have with any third party (e.g., a former employer) that may limit Executive’s ability to perform Executive’s duties to the Company, or which could present a conflict of
interest with the Company, including but not limited to disclosure (and a copy) of any contractual restrictions on solicitations or competitive activities. Executive represents and warrants that Executive does not possess confidential information
arising out of prior employment, consulting, or other third party relationships, that would be used in connection with Executive’s employment by the Company, except as expressly authorized by that third party. During Executive’s employment
by the Company, Executive will use in the performance of Executive’s duties only information that is generally known and used by persons with training and experience comparable to Executive’s own, common knowledge in the industry,
otherwise legally in the public domain, or obtained or developed by the Company or by Executive in the course of Executive’s work for the Company. 

8.         Outside Activities and Non-Competition During
Employment. 
 8.1 Outside Activities. Throughout Executive’s employment with the Company, Executive may engage in civic and not-for-profit activities so long as such activities do not interfere with the performance of Executive’s duties hereunder or present a conflict of interest with the
Company or its affiliates. Subject to the restrictions set forth herein, and only with prior written disclosure to and written consent of the Board, Executive may engage in other types of business or public activities. The Board may rescind such
consent, if the Board determines, in its sole discretion, that such activities compromise or threaten to compromise the Company’s or its affiliates’ business interests or conflict or compete with Executive’s duties to the Company or
its affiliates. 

  
 3. 

 8.2 Non-Competition During Employment. Throughout Executive’s employment with
the Company, Executive will not, without the express written consent of the Board, directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor, investor, joint venturer, associate, representative or consultant of
any person or entity engaged in, or planning or preparing to engage in, business activity competitive with any line of business engaged in (or planned to be engaged in) by the Company or its affiliates; provided, however, that Executive may purchase
or otherwise acquire up to (but not more than) one percent (1%) of any class of securities of any enterprise (without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange.
In addition, Executive will be subject to certain restrictions (including restrictions continuing after Executive’s employment ends) under the terms of the Proprietary Information Agreement. 

9.         Termination of Employment; Severance and Change in Control Benefits. 

9.1 At-Will Employment. Executive’s employment relationship is at-will. Either Executive or the Company may terminate the
employment relationship at any time, with or without Cause (as defined below) or Good Reason (as defined below) or advance notice. 
 9.2
Termination Without Cause or Resignation for Good Reason Unrelated to Change in Control. In the event Executive’s employment with the Company is terminated by the Company without Cause (and other than as a result of
Executive’s death or disability) or Executive resigns for Good Reason, in either case, at any time except during the Change in Control Period (as defined below) then provided such termination or resignation constitutes a “separation from
service” (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from Service”), and provided that Executive satisfies the Release Requirement in
Section 10 below and remains in compliance with the terms of this Agreement, the Company shall provide Executive with the following “Severance Benefits”: 

(i) Severance Payment. Severance pay in the form of a lump sum payment equal to 12 months of Executive’s final Base Salary for the
year in which the termination date occurs, payable within sixty (60) days following the termination date and subject to required payroll deductions and tax withholdings (the “Severance Payment”); provided, however that, if
the period for satisfaction of the Release Requirement (as defined below) begins in one taxable year and ends in another taxable year, payment shall not be made until the beginning of the second taxable year. For such purposes, Executive’s
final Base Salary will be calculated prior to giving effect to any reduction in Base Salary that would give rise to Executive’s right to resign for Good Reason. 

(ii) Health Care Continuation Coverage Payments. 

(a) COBRA Premiums. If Executive timely elects continued coverage under COBRA, the Company will pay Executive’s COBRA premiums to
continue Executive’s coverage (including coverage for Executive’s eligible dependents, if applicable) (“COBRA Premiums”) through the period starting on the termination date and ending twelve (12) months after the
termination date (the “COBRA Premium Period”); provided, however, that the Company’s provision of such COBRA Premium benefits will immediately cease if during the COBRA Premium Period Executive becomes eligible for group health
insurance coverage through a new employer or Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event Executive becomes covered under another employer’s group health plan or
otherwise ceases to be eligible for COBRA during the COBRA Premium Period, Executive must immediately notify the Company of such event. 

(b) Special Cash Payments in Lieu of COBRA Premiums. Notwithstanding the foregoing, if the Company determines, in its sole discretion,
that it cannot pay the COBRA Premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act) or that it is otherwise not administratively
reasonable to do so, regardless of whether Executive or Executive’s dependents elect or are eligible for COBRA coverage, the Company instead shall pay to Executive, on the first day of each calendar month following the termination date, a fully
taxable cash payment equal to the applicable COBRA premiums for that month (including the amount of COBRA premiums for Executive’s eligible dependents), less required payroll deductions and withholdings (such amount, the “Special Cash
Payment”), for the remainder of the COBRA Premium Period. Executive may, but is not obligated to, use such Special Cash Payments toward the cost of COBRA premiums. 

  
 4. 

 (iii) Equity Acceleration. Notwithstanding anything to the contrary set forth in the
Equity Plan or award agreement, effective as of Executive’s employment termination date, the portion of the then-unvested Time-Based Option that would have vested and become exercisable within the 12 month period following such termination will
become immediately vested and exercisable by Executive upon such termination and shall remain exercisable, if applicable, following Executive’s termination as set forth in the applicable equity award documents. 

9.3 Termination Without Cause or Resignation for Good Reason During Change in Control Period. In the event Executive’s
employment with the Company is terminated by the Company without Cause (and other than as a result of Executive’s death or disability) at any time during the Change in Control Period or Executive resigns for Good Reason at any time during the
Change in Control Period, in lieu of (and not additional to) the Severance Benefits described in Section 9.2, and provided that Executive satisfies the Release Requirement in Section 10 below and remains in compliance with the terms of
this Agreement, the Company shall instead provide Executive with the following “CIC Severance Benefits”. For the avoidance of doubt: (A) in no event will Executive be entitled to severance benefits under Section 9.2 and
this Section 9.3, and (B) if the Company has commenced providing Severance Benefits to Executive under Section 9.2 prior to the date that Executive becomes eligible to receive CIC Severance Benefits under this Section 9.3, the
Severance Benefits previously provided to Executive under Section 9.2 of this Agreement shall reduce the CIC Severance Benefits provided under this Section 9.3: 

(i) CIC Severance Payment. Severance pay in the form of a lump sum payment equal to 24 months of Executive’s final Base Salary for
the year in which the termination date occurs, payable within sixty (60) days following the termination date and subject to required payroll deductions and tax withholdings (the “CIC Severance Payment”); provided, however that,
if the period for satisfaction of the Release Requirement (as defined below) begins in one taxable year and ends in another taxable year, payment shall not be made until the beginning of the second taxable year. For such purposes, Executive’s
final Base Salary will be calculated prior to giving effect to any reduction in Base Salary that would give rise to Executive’s right to resign for Good Reason. 

(ii) CIC Health Care Continuation Coverage Payments. 

(a) COBRA Premiums. If Executive timely elects continued coverage under COBRA, the Company will pay Executive’s COBRA premiums to
continue Executive’s coverage (including coverage for Executive’s eligible dependents, if applicable) (“CIC COBRA Premiums”) through the period starting on the termination date and ending twenty-four (24) months after
the termination date (the “CIC COBRA Premium Period”); provided, however, that the Company’s provision of such CIC COBRA Premium benefits will immediately cease if during the CIC COBRA Premium Period Executive becomes eligible
for group health insurance coverage through a new employer or Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event Executive becomes covered under another employer’s group
health plan or otherwise ceases to be eligible for COBRA during the CIC COBRA Premium Period, Executive must immediately notify the Company of such event.  

(b) Special Cash Payments in Lieu of CIC COBRA Premiums. Notwithstanding the foregoing, if the Company determines, in its sole
discretion, that it cannot pay the CIC COBRA Premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act) or that it is otherwise not
administratively reasonable to do so, regardless of whether Executive or Executive’s dependents elect or are eligible for COBRA coverage, the Company instead shall pay to Executive, on the first day of each calendar month following the
termination date, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including the amount of COBRA premiums for Executive’s eligible dependents), subject to applicable tax withholdings (such amount, the
“Special CIC Cash Payment”), for the remainder of the CIC COBRA Premium Period. Executive may, but is not obligated to, use such Special CIC Cash Payments toward the cost of COBRA premiums.  

  
 5. 

 (iii) Equity Acceleration. Notwithstanding anything to the contrary set forth in the
Equity Plan or award agreement, effective as of Executive’s employment termination date, the then-unvested portion of the Time-Based Option will become immediately vested and exercisable by Executive upon such termination and shall remain
exercisable, if applicable, following Executive’s termination as set forth in the applicable equity award documents.  
 9.4
Termination for Cause; Resignation Without Good Reason; Death or Disability. Executive will not be eligible for, or entitled to any severance benefits, including (without limitation) the Severance Benefits and CIC Severance Benefits listed in
Sections 9.2 and 9.3 above, if the Company terminates Executive’s employment for Cause, Executive resigns Executive’s employment without Good Reason, or Executive’s employment terminates due to Executive’s death or disability.
 
 9.5 Other. If Executive materially breaches any continuing obligations to the Company (including but not limited to any
material breach of the Proprietary Information Agreement) during the period of time that Executive is receiving any Severance Benefits or CIC Severance Benefits, Executive will forfeit Executive’s entitlement to any then unpaid Severance
Benefits (or CIC Severance Benefits, as applicable), and the Company’s obligation to continue to pay or provide such benefits will immediately terminate as of the date of Executive’s material breach. 

10.         Conditions to Receipt of Severance Benefits. To be eligible for any of the Severance
Benefits or CIC Severance Benefits pursuant to Sections 9.2 or 9.3 above, Executive must satisfy the following release requirement (the “Release Requirement”): return to the Company a signed and dated general release of all known
and unknown claims in a termination agreement acceptable to the Company and the Executive (the “Release”) within the applicable deadline set forth therein, but in no event later than forty-five (45) days following
Executive’s termination date, and permit the Release to become effective and irrevocable in accordance with its terms (such effective date of the Release, the “Release Effective Date”). No Severance Benefits will be provided
hereunder prior to the Release Effective Date. Accordingly, if Executive breaches the preceding sentence and/or refuses to sign and deliver to the Company an executed Release or signs and delivers to the Company the Release but exercises
Executive’s right, if any, under applicable law to revoke the Release (or any portion thereof), then Executive will not be entitled to any severance, payment or benefit under this Agreement. 

11.         Section 409A. It is intended that all of the severance benefits
and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent no so exempt,
this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive’s right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a
series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company
at the time of Executive’s Separation from Service to be a “specified employee” for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other
agreement with the Company are deemed to be “deferred compensation”, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i)
and the related adverse taxation under Section 409A, such payments shall not be provided to Executive prior to the earliest of (i) the expiration of the six-month and one day period measured from the
date of Executive’s Separation from Service with the Company, (ii) the date of Executive’s death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation. Upon the first business
day following the 

  
 6. 

 expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to
this Paragraph shall be paid in a lump sum to Executive, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred. If the Company determines that
any severance benefits provided under this Agreement constitutes “deferred compensation” under Section 409A, for purposes of determining the schedule for payment of the severance benefits, the effective date of the Release will not be
deemed to have occurred any earlier than the sixtieth (60th) date following the Separation From Service, regardless of when the Release actually becomes effective. In addition to the above, to the extent required to comply with Section 409A and
the applicable regulations and guidance issued thereunder, if the applicable deadline for Executive to execute (and not revoke) the applicable Release spans two calendar years, payment of the applicable severance benefits shall not commence until
the beginning of the second calendar year. To the extent required to avoid accelerated taxation and/or tax penalties under Code Section 409A, amounts reimbursable to Executive under this Agreement shall be paid to Executive on or before the
last day of the year following the year in which the expense was incurred and the amount of expenses eligible for reimbursement (and in-kind benefits provided to Executive) during any one year may not effect
amounts reimbursable or provided in any subsequent year. The Company makes no representation that any or all of the payments described in this Agreement will be exempt from or comply with Code Section 409A and makes no undertaking to preclude
Code Section 409A from applying to any such payment. 
 12.
        Section 280G; Limitations on Payment. 
 12.1 If any payment or
benefit Executive will or may receive from the Company or otherwise (a “280G Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this
sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then any such 280G Payment provided pursuant to this Agreement (a “Payment”) shall be equal to the Reduced Amount.
The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including
the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the
highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the
Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the “Reduction
Method”) that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the 

“Pro Rata Reduction Method”). 

12.2 Notwithstanding any provision of Section 12.1 to the contrary, if the Reduction Method or the Pro Rata Reduction Method would
result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be,
shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as
determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments
that are not contingent on future events; and (C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred
compensation within the meaning of Section 409A. 
 12.3 Unless Executive and the Company agree on an alternative accounting
firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control transaction shall perform the foregoing calculations. If the accounting firm so engaged by the
Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required by this
Section 12. 

  
 7. 

 The Company shall bear all expenses with respect to the determinations by such accounting or law firm
required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to
Executive and the Company within fifteen (15) calendar days after the date on which Executive’s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by Executive or the Company) or such other time as
requested by Executive or the Company. 
 12.4 If Executive receives a Payment for which the Reduced Amount was determined pursuant to
clause (x) of Section 12.1 and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Executive agrees to promptly return to the Company a sufficient amount of the Payment (after
reduction pursuant to clause (x) of Section 12.1) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of Section 12.1,
Executive shall have no obligation to return any portion of the Payment pursuant to the preceding sentence. 
 13.
        Definitions. 
 13.1 Cause. For the purposes of this Agreement,
“Cause” means the occurrence of any one or more of the following: (i) Executive’s conviction of or plea of guilty or nolo contendere to any felony or a crime of moral turpitude; (ii) Executive’s willful and
continued failure or refusal to: a) follow lawful and reasonable policies and regulations of the Company or its affiliates; or b) to perform the assigned duties of his employment with the Company or its affiliates; (iii) unprofessional,
unethical, immoral or fraudulent conduct by Executive that is materially detrimental to the reputation, character and standing of the Company or any affiliate; or (iv) Executive’s material breach of this Agreement, the Proprietary
Information Agreement, or any written Company agreement or policies so long as, in any case, with respect to items (ii)-(iv) above, (x) the Company has provided notice to the Executive setting forth in reasonable detail the specific conduct of
the Executive that constitutes Cause within thirty (30) days of the date the Company first becomes aware of its existence, (y) the Executive has failed to cure such conduct (if such conduct is capable of being cured) within thirty
(30) days following the date of receipt of such notice, and (z) the Company has terminated the Executive’s employment within thirty (30) days following such failure to cure.  

13.2 Change in Control. For the purposes of this Agreement, “Change in Control” shall have the meaning described
in the Company’s Equity Plan. 
 13.3 Change in Control Period. For the purposes of this Agreement, “Change in Control
Period” means the time period commencing three (3) months before the effective date of a Change in Control and ending on the date that is twelve (12) months after the effective date of a Change in Control. 

13.4 Good Reason. “Good Reason” means the occurrence of any of the following events without Employee’s prior written
consent: (A) a material reduction in Base Salary, (B) any material diminution in the Executive’s authority, duties or responsibilities, (C) a relocation of the Executive’s principal place of employment to a location that
increases Executive’s one-way commute from the Executive’s principal place of employment under Section 1.2 by more than 25 miles, or (D) any material breach by the Company of any material
obligation under this Agreement or any written agreement between the Executive and the Company, so long as, in any case, (x) the Executive has provided notice to the Company setting forth in reasonable detail the specific conduct of the Company
that constitutes Good Reason within thirty (30) days of the date the Executive first becomes aware of its existence, (y) the Company has failed to cure such conduct within thirty (30) days following the date of receipt of such notice,
and (z) the Executive has terminated his employment within thirty (30) days following such failure to cure. 
 14.
        Dispute Resolution. Executive shall agree to and execute the standard terms of the Mutual Agreement to Arbitrate Claims (MAAC) with Company, provided to Executive separately and executed
concurrently herewith. 

  
 8. 

 15.         General Provisions. 

15.1 Notices. Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery (including
personal delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll. 

15.2 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any
other provision of this Agreement, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties. 

15.3 Waiver. Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not thereby
be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. 
 15.4 Complete
Agreement. This Agreement, together with the Proprietary Information Agreement and MAAC, constitutes the entire agreement between Executive and the Company with regard to the subject matter hereof and is the complete, final, and exclusive
embodiment of the Company’s and Executive’s agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and
it supersedes and replaces any other agreements or promises made to Executive by anyone concerning Executive’s employment terms, compensation or benefits, whether oral or written (including but not limited any agreements or promises with or
from the Company or any of its affiliates or predecessors). It cannot be modified or amended except in a writing signed by a duly authorized officer of the Company, with the exception of those changes expressly reserved to the Company’s
discretion in this Agreement. 
 15.5 Counterparts. This Agreement may be executed in separate counterparts, any one of which need not
contain signatures of more than one party, but both of which taken together will constitute one and the same Agreement. 
 15.6
Headings. The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof. 

15.7 Successors and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the
Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of Executive’s duties hereunder and Executive may not assign any of Executive’s rights hereunder without the
written consent of the Company, which shall not be withheld unreasonably. 
 15.8 Tax Withholding. All payments and awards
contemplated or made pursuant to this Agreement will be subject to withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company
has neither made any assurances nor any guarantees concerning the tax treatment of any payments or awards contemplated by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully
understands the tax and economic consequences of all payments and awards made pursuant to this Agreement. 
 15.9 Choice of Law. All
questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of California. 

  
 9. 

 15.10 Allowable Disclosures. Notwithstanding anything to the contrary in this
Agreement or elsewhere, nothing shall prohibit the Executive from reporting violations or possible violations of law or regulation to a governmental agency or other entity, including but not limited to the U.S. Securities and Exchange Commission,
the Financial Industry Regulatory Authority, the U.S. Commodity Futures Trading Commission, the U.S. Consumer Financial Protection Bureau, the U.S. Department of Justice, the U.S. Congress, any agency Inspector General, the U.S. Equal Employment
Opportunity Commission or the U.S. National Labor Relations Board (the “Government Agencies”), and the Executive shall not be required to provide notification to, or receive prior approval from, the Company regarding any such report. The
Executive further understands that this Agreement does not limit his ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing
documents or other information, without notice to the Company. Furthermore, this Agreement does not limit the Executive’s right to receive an award for information provided to any Government Agencies. Notwithstanding the foregoing, nothing
herein shall constitute a waiver by the Company of the attorney-client privilege, the attorney work-product doctrine, or applicable company policy. 

IN WITNESS WHEREOF, the Parties have executed this Agreement on the day and year first
written above. 
  

			
	1LIFE HEALTHCARE, INC.
		
	By:	 	 /s/ Bruce Dunlevie

		 	Bruce Dunlevie
	
	EXECUTIVE
	
	 /s/ Amir Dan Rubin

	AMIR DAN RUBIN

  
 10.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]